Moberg Pharma granted U.S. patent relating to improved dosing of MOB-015
STOCKHOLM, Nov. 3, 2026 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) today announced that the United States Patent and Trademark Office (USPTO) has granted a patent relating to an improved dosing regimen for MOB-015, the company's topical drug for onychomycosis. The U.S. is the first...
Covered in this story
Call it yourself
No calls on $MOB yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Mobilicom →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.